AU2007326838B9 - Genetic susceptibility variants of Type 2 diabetes mellitus - Google Patents

Genetic susceptibility variants of Type 2 diabetes mellitus Download PDF

Info

Publication number
AU2007326838B9
AU2007326838B9 AU2007326838A AU2007326838A AU2007326838B9 AU 2007326838 B9 AU2007326838 B9 AU 2007326838B9 AU 2007326838 A AU2007326838 A AU 2007326838A AU 2007326838 A AU2007326838 A AU 2007326838A AU 2007326838 B9 AU2007326838 B9 AU 2007326838B9
Authority
AU
Australia
Prior art keywords
seq
diabetes
markers
allele
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007326838A
Other languages
English (en)
Other versions
AU2007326838B2 (en
AU2007326838A1 (en
Inventor
Valgerdur Steinthorsdottir
Gudmar Thorleifsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Decode Genetics ehf
Original Assignee
Decode Genetics ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics ehf filed Critical Decode Genetics ehf
Publication of AU2007326838A1 publication Critical patent/AU2007326838A1/en
Publication of AU2007326838B2 publication Critical patent/AU2007326838B2/en
Application granted granted Critical
Publication of AU2007326838B9 publication Critical patent/AU2007326838B9/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AU2007326838A 2006-11-30 2007-11-30 Genetic susceptibility variants of Type 2 diabetes mellitus Ceased AU2007326838B9 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IS8572 2006-11-30
IS8572 2006-11-30
IS8630 2007-04-04
IS8630 2007-04-04
PCT/IS2007/000020 WO2008065682A2 (en) 2006-11-30 2007-11-30 Genetic susceptibility variants of type 2 diabetes mellitus

Publications (3)

Publication Number Publication Date
AU2007326838A1 AU2007326838A1 (en) 2008-06-05
AU2007326838B2 AU2007326838B2 (en) 2014-01-30
AU2007326838B9 true AU2007326838B9 (en) 2014-02-13

Family

ID=39102918

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007326838A Ceased AU2007326838B9 (en) 2006-11-30 2007-11-30 Genetic susceptibility variants of Type 2 diabetes mellitus

Country Status (8)

Country Link
US (1) US20100086921A1 (enExample)
EP (1) EP2099937A2 (enExample)
JP (2) JP2010510804A (enExample)
KR (1) KR20090087486A (enExample)
AU (1) AU2007326838B9 (enExample)
CA (1) CA2683909A1 (enExample)
SG (1) SG177148A1 (enExample)
WO (1) WO2008065682A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008065544A2 (en) * 2006-09-11 2008-06-05 Mcgill University Genetic predictors of risk for type 2 diabetes mellitus
WO2010128530A1 (en) * 2009-05-08 2010-11-11 Decode Genetics Ehf Genetic variants contributing to risk of prostate cancer
AU2010269841A1 (en) * 2009-07-10 2012-02-23 Decode Genetics Ehf Genetic markers associated with risk of diabetes mellitus
JP5954724B2 (ja) * 2011-07-25 2016-07-20 国立研究開発法人理化学研究所 第６染色体短腕２２領域または第９染色体長腕２１領域の一塩基多型に基づく肥満の検査方法
WO2014156196A1 (ja) * 2013-03-29 2014-10-02 一般社団法人ファルマバレープロジェクト支援機構 ２型糖尿病治療剤
KR101459057B1 (ko) * 2014-02-27 2014-11-12 서울대학교병원 (분사무소) 임신성 당뇨병 이후 제2형 당뇨병 발병 예측 방법
CN110218781B (zh) * 2019-04-23 2023-03-31 河北医科大学 21个微单倍型位点的复合扩增体系、下一代测序分型试剂盒及分型方法
WO2022203533A1 (ru) * 2021-03-25 2022-09-29 Владимир Валерьевич ВОЛОБУЕВ Способ оценки предрасположенности к различным формам сахарного диабета 2го типа

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5288611A (en) * 1983-01-10 1994-02-22 Gen-Probe Incorporated Method for detecting, identifying, and quantitating organisms and viruses
DE3486488T2 (de) * 1983-01-10 2003-04-03 Gen-Probe Inc., San Diego Verfahren zum Nachweis, Identifizieren und Quantifizieren von Organismen und Viren
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5424186A (en) * 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5288644A (en) * 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5384261A (en) * 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5837832A (en) * 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5858659A (en) * 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
AU1450900A (en) * 1998-10-21 2000-05-08 Arch Development Corporation Methods of treatment of type 2 diabetes
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
JP2006506988A (ja) * 2002-11-01 2006-03-02 デコード ジェネティクス イーエッチエフ． 染色体５ｑ３５に位置したヒトＩＩ型糖尿病遺伝子−ＳＬＩＴ−３
US20050196784A1 (en) * 2002-11-01 2005-09-08 Decode Genetics Ehf. Human Type II diabetes gene - Kv channel-interacting protein (KChIP1) located on chromosome 5
EP1774029B1 (en) * 2004-07-16 2013-04-24 DSM IP Assets B.V. Method for detecting the risk of type 2 diabetes
US20070048751A1 (en) * 2005-02-15 2007-03-01 Jae-Heup Kim Method of diagnosing type II diabetes mellitus using multilocus marker, polynucleotide including marker associated with type II diabetes mellitus, and microarray and diagnostic kit including the polynucleotide
EP1869214A2 (en) * 2005-03-25 2007-12-26 Novartis AG Biomarkers for pharmacogenetic diagnosis of type 2 diabetes
JP2006296270A (ja) * 2005-04-19 2006-11-02 Univ Of Tokyo Ｐｒｋａａ２遺伝子多型による２型糖尿病発症素因の検出方法
WO2006137085A1 (en) * 2005-06-20 2006-12-28 Decode Genetics Ehf. Genetic variants in the tcf7l2 gene as diagnostic markers for risk of type 2 diabetes mellitus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MATSUZAKI, H. et al., Nature Methods, 2004, vol. 1, no. 2, pp109-111 *
NCBI Probe Accession no. Pr003269110 retrieved on 6 February 2013 from internet URL http://www.ncbi.nlm.nih.gov/probe?term=rs9460517 *

Also Published As

Publication number Publication date
AU2007326838B2 (en) 2014-01-30
WO2008065682A3 (en) 2008-10-16
SG177148A1 (en) 2012-01-30
JP2014097060A (ja) 2014-05-29
JP2010510804A (ja) 2010-04-08
AU2007326838A1 (en) 2008-06-05
CA2683909A1 (en) 2008-06-05
WO2008065682A2 (en) 2008-06-05
US20100086921A1 (en) 2010-04-08
EP2099937A2 (en) 2009-09-16
KR20090087486A (ko) 2009-08-17

Similar Documents

Publication Publication Date Title
AU2008256219B2 (en) Genetic variants on Chr 5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
EP2121979B1 (en) Genetic markers for risk management of cardiac arrhythmia
AU2008212117B2 (en) Genetic variants contributing to risk of prostate cancer
US8796182B2 (en) Genetic markers associated with risk of diabetes mellitus
EP2414543B1 (en) Genetic markers for risk management of atrial fibrillation and stroke
EP2527466A2 (en) Genetic variants on CHR2 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
CA2729931A1 (en) Genetic variants predictive of cancer risk in humans
AU2007326838B2 (en) Genetic susceptibility variants of Type 2 diabetes mellitus
US20100160802A1 (en) Genetic Variants as Markers for Use in Diagnosis, Prognosis and Treatment of Eosinophilia, Asthma, and Myocardial Infarction
CA2729934A1 (en) Genetic variants for breast cancer risk assessment
NZ577804A (en) Genetic susceptibility variants of type 2 diabetes mellitus
US20100047807A1 (en) Genetic variants associated with periodic limb movements and restless legs syndrome
HK1167164B (en) Genetic markers for risk management of atrial fibrillation and stroke
HK1139183A (en) Genetic markers for risk management of cardiac arrhythmia
HK1139183B (en) Genetic markers for risk management of cardiac arrhythmia

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired